SIETES :: 92806 citas

Resultados de la búsqueda por TROSPIO REFINAR BÚSQUEDA

1.

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019:24 de junio. [Ref.ID 103160]

2.

Balk EM, Rofeberg VN, Adam GP, Kimmel HJ, Trikalinos TA, Jeppson PC. Pharmacologic and nonpharmacologic treatments for urinary incontinence in women: a systematic review and network meta-analysis of clinical outcomes. Ann Intern Med 2019;170:2 de abril. [Ref.ID 103066]

3.

D'Silva M, Hallas J, Pottegård A, Kristiansen NS, Atsma WJ, Franks B, D'Silva M, Varas-Lorenzo C, Perez-Gutthann S, Arana J. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. Eur J Clin Pharmacol 2018;74:febrero. [Ref.ID 102545]

4.

Park H-Y, Park J-W, Sohn HS, Kwon JW. Association of parkinsonism or Parkinson disease with polypharmacy in the year preceding diagnosis: a nested case–control study in South Korea . Drug Saf 2017;40:1109-18. [Ref.ID 102104]

5.

Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. JAMA Intern Med 2015;175:408-9. [Ref.ID 98843]

6.

Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Krane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. JAMA Intern Med 2015;175:401-7. [Ref.ID 98842]

7.

Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]

8.

Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MFR, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF, for the Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med 2012;367:1803-13. [Ref.ID 94025]

9.

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a sytematic review. Ann Intern Med 2012;156:857-60. [Ref.ID 93318]

10.

Anónimo. Constipations d'origine médicamenteuse chez les adultes. Prescrire 2012;32:430-5. [Ref.ID 93122]

11.

Anónimo. Myopie, hypermétropie et troubles de l'accommodation d'origine médicamenteuse. Prescrire 2010;30:24-8. [Ref.ID 87603]

12.

Anónimo. Enrichir sa panoplie thérapeutique. Bilan de l'année 2008. Cardiologie. Prescrire 2009;29:31-2. [Ref.ID 84808]

13.

Anónimo. Trospium: allongement de l'intervalle QT. Prescrire 2008;28:346. [Ref.ID 82818]

14.

Anónimo. Update on drugs for overactive bladder syndrome. Drug Ther Bull 2007;45:44-8. [Ref.ID 80210]

15.

Anónimo. Maladie d'Alzheimer: gare aux interactions avec les anticholinestérasiques. Prescrire 2006;26:111-5. [Ref.ID 76120]

16.

Dmochowski R. Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf 2005;28:583-600. [Ref.ID 74323]

17.

Anónimo. Solifenacina. Vesicare (Yamanouchi), en incontinencia urinaria de urgencia. PAM 2005;29:274-92. [Ref.ID 73895]

18.

Anónimo. Solifénacine. "Hyperactivité vésicale": 5e anticholinergique d'intérêt clinique douteux. Prescrire 2005;25:336-8. [Ref.ID 73738]

19.

Rovner E S. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46. [Ref.ID 72826]

20.

Anónimo. Trospium chloride (Sanctura): another anticholinergic for overactive bladder. Med Lett Drugs Ther 2004;46:63-4. [Ref.ID 71190]